Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors

American Journal of Hematology

Volumn 83, Issue 4, 2008, Pages 296-302

  Ou, Joyce ^a   Vergilio, Jo Anne ^b   Bagg, Adam ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; ARAC PROTEIN; BCR ABL PROTEIN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTARABINE; DASATINIB; IMATINIB; INTERFERON; NILOTINIB; PHOSPHOTRANSFERASE;

ALLOGENEIC STEM CELL TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; LABORATORY TEST; MOLECULAR MECHANICS; PATHOGENESIS; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW;

ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG MONITORING; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASM PROTEINS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 41449091487     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21096     Document Type: Review

References (61)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-1340.
2. Vergilio J, Bagg A. Chronic myelogenous leukemia: Molecular diagnosis and monitoring. In: Fuchs J, Podda M, editors. Encyclopedia of Medical Genomics and Proteomics. New York: Marcel Dekker; 2005. pp 252-258.
3. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497-1499.
4. Shtivelman E, Lifshitz B, Gale RP, et al. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell 1986;47:277-284.
5. Fialkow PJ, Martin PJ, Najfeld V, et al. Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood 1981;58:158-163.
6. Ress A, Moelling K. Bcr is a negative regulator of the Wnt signalling pathway. EMBO Rep 2005;6:1095-1100.
7. Olabisi OO, Mahon GM, Kostenko EV, et al. Bcr interacts with components of the endosomal sorting complex required for transport-I and is required for epidermal growth factor receptor turnover. Cancer Res 2006;66:6250-6257.
8. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004;103:4010-4022.
9. Savage DG, Antman KH. Imatinib mesylate - A new oral targeted therapy. N Engl J Med 2002;346:683-693.
10. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996;88:2375-2384.
11. Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer 2003;98:1337-1354.
12. Heisterkamp N, Jenster G, ten Hoeve J, et al. Acute leukaemia in bcr/abl transgenic mice. Nature 1990;344:251-253.
13. Lugo TG, Pendergast AM, Muller AJ, et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079-1082.
14. McLaughlin J, Chianese E, Witte ON. Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol Cell Biol 1989;9:1866-1874.
15. Elliott MA, Hanson CA, Dewald GW, et al. WHO-defined chronic neutrophilic leukemia: A long-term analysis of 12 cases and a critical review of the literature. Leukemia 2005;19:313-317.
16. Pane F, Frigeri F, Sindona M, et al. Neutrophilic-chronic myeloid leukemia: A distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996;88:2410-2414.
17. Shteper PJ, Ben-Yehuda D. Molecular evolution of chronic myeloid leukaemia. Semin Cancer Biol 2001;11:313-323.
18. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002;107:76-94.
19. Huntly BJ, Bench A, Green AR. Double jeopardy from a single translocation: Deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 2003;102:1160-1168.
20. Kreil S, Pfirrmann M, Haferlach C, et al. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood 2007;110:1283-1290.
21. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-1820.
22. Luthra R, Sanchez-Vega B, Jeffrey Medeiros L. TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. Mod Pathol 2004;17:96-103.
23. Wells SJ, Phillips CN, Winton EF, et al. Reverse transcriptase-polymerase chain reaction for bcr/abl fusion in chronic myelogenous leukemia. Am J Clin Pathol 1996;105:756-760.
24. Vergilio J, Bagg A. Myeloproliferative disorders and myelodysplastic syndromes. In: Kaul K, Leonard DGB, Caliendo AM, Bagg A, van Deerlin V, editors. Molecular Pathology in Clinical Practice. New York: Springer-Verlag; 2006. pp 383-398.
25. Dessars B, El Housni H, Lambert F, et al. Rational use of the EAC real-time quantitative PCR protocol in chronic myelogenous leukemia: report of three false-negative cases at diagnosis. Leukemia 2006;20:886-888.
26. Branford S, Rudzki Z, Harper A, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003;17:2401-2409.
27. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-1432.
28. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
29. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
30. Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL positive leukemias treated with imatinib in a single center: A 4.5-year follow-up. Cancer 2005;103:1659-1669.
31. Sureda A, Carrasco M, de Miguel M, et al. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Haematologica 2003;88:1213-1220.
32. Jabbour E, Kantarjian HM, Abruzzo L, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2007;110:2991-2995.
33. Tefferi A, Dewald GW, Litzow ML, et al. Chronic myeloid leukemia: Current application of cytogenetics and molecular testing for diagnosis and treatment. Mayo Clin Proc 2005;80:390-402.
34. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37.
35. Wang L, Pearson K, Ferguson JE, et al. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol 2003;120:990-999.
36. Marin D, Kaeda J, Szydlo R, et al. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: Patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia 2005;19:507-512.
37. Branford S, Cross NC, Hochhaus A, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006;20:1925-1930.
38. Saldanha J, Silvy M, Beaufils N, et al. Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: Towards new standards for gene expression measurements. Leukemia 2007;21:1481-1487.
39. Mauro MJ. Defining and managing imatinib resistance. Hematology Am Soc Hematol Educ Program 2006:219-225.
40. Deininger MW. Optimizing therapy of chronic myeloid leukemia. Exp Hematol 2007;35:144-154.
41. Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett 2007;249:121-132.
42. Shah NP. Loss of response to imatinib: Mechanisms and management. Hematology Am Soc Hematol Educ Program 2005:183-187.
43. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002;100:1965-1971.
44. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 2002;99:3530-3539.
45. Guilhot F. Sustained durability of responses plus high rates of cytogenetic responses result in long-term benefit for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib (IM) therapy: Update from the IRIS Study [abstract]. Program and abstracts of the 46th Annual Meeting of the American Society of Hematology, 2004. Abstract 21.
46. Hochhaus A, Hughes T. Clinical resistance to imatinib: Mechanisms and implications. Hematol Oncol Clin North Am 2004;18:641-656, ix.
47. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006;12:7374-7579.
48. Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 2004;11:35-43.
49. Branford S, Rudzki Z, Walsr S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276-283.
50. Martinelli G, Soverini S, Rosti G, et al. Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leikemia 2005;19:1872-1879.
51. Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: Correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005;106:2128-2137.
52. Mughal T, Cortes J, Cross NC, et al. Chronic myeloid leukemia - Some topical issues. Leukemia 2007;21:13-1347-1352.
53. Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004;104:2926-2932.
54. Branford S, Hughes T. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med 2006;125:93-106.
55. Ohno R, Nakamura Y. Predict on of response to imatinib by cDNA microarray analysis. Semin Hematol 2003;40:42-49.
56. Kantarjian HM, Cortes J, Guilhot F, et al. Diagnosis and management of chronic myeloid leukemia: A survey of American and European practice patterns. Cancer 2007;109:1365-1375.
57. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-4505.
58. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic nyeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial. Blood 2007;109:5143-5150.
59. Soverini S, Colarossi S, Gnari A, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 2007;92:401-404.
60. Cheetham GM, Charlton PA, Golec JM, et al. Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett 2007;251:323-329.
61. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance and the road to a cure of chronic myeloid leukemia. Blood 2007;110:2242-2249.